secwatch.observer — SEC 8-K summary
======================================

Issuer:     Crinetics Pharmaceuticals, Inc. (CRNX)
CIK:        0001658247
Form:       8-K
Filed at:   2024-10-16T23:59:59+00:00
Accession:  0001193125-24-238120
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Crinetics COO James Hassard departs; consulting deal through Jan 2025 at $200/hr
--------------------------------------------------------------------------------

- James Hassard ceased as COO effective Oct 14, 2024; consulting and separation agreements signed Oct 10.
- Consulting agreement: up to 20 hrs/month at $200/hr through Jan 15, 2025 for commercial launch prep.
- Separation agreement provides payments/benefits for termination without cause per employment contract.
- Outstanding equity awards continue to vest through Jan 15, 2025; prior employment agreement terminated.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1658247/000119312524238120/0001193125-24-238120-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1658247/000119312524238120/d850938d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-238120

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer